UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Higher infliximab trough levels are associated with perianal fistula healing in patients with Crohn's disease

Alimentary pharmacology & therapeutics, 2017-04, Vol.45 (7), p.933-940

2017

Volltextzugriff (PDF)

The incidence and risk factors for developing depression after being diagnosed with inflammatory bowel disease: a cohort study

Alimentary pharmacology & therapeutics, 2014-04, Vol.39 (8), p.802-810

2014

Volltextzugriff (PDF)

Vedolizumab in patients with concurrent primary sclerosing cholangitis and inflammatory bowel disease does not improve liver biochemistry but is safe and effective for the bowel disease

Alimentary pharmacology & therapeutics, 2018-03, Vol.47 (6), p.753-762

2018

Volltextzugriff (PDF)

Letter: psychological remission ‐ a future endpoint in inflammatory bowel disease? Authors’ reply

Alimentary pharmacology & therapeutics, 2014-06, Vol.39 (12), p.1436-1437

2014

Volltextzugriff (PDF)

Letter: is there a bi‐directional relationship between depression and IBD? Authors' reply

Alimentary pharmacology & therapeutics, 2014-07, Vol.40 (2), p.214-214

2014

Volltextzugriff (PDF)

Higher Adalimumab Concentration Is Associated With Complete Fistula Healing in Patients With Perianal Fistulizing Crohn’s Disease

Clinical gastroenterology and hepatology, 2024-10, Vol.22 (10), p.2134-2136.e2

2024

Volltextzugriff (PDF)

P739 Translating Pharmacokinetic and Efficacy Outcomes of NLRX1 Agonist NX-13: Contrasting a Pig Model and a Human Phase 1b Clinical Trial in Ulcerative Colitis

Journal of Crohn's and colitis, 2024-01, Vol.18 (Supplement_1), p.i1384-i1384

2024

Volltextzugriff (PDF)

P114 Role of NLRX1 Agonist NX-13 in Reducing Visceral Hypersensitivity in Preclinical Gastrointestinal Inflammation

Journal of Crohn's and colitis, 2024-01, Vol.18 (Supplement_1), p.i400-i401

2024

Volltextzugriff (PDF)

POSA96 The Economic Burden of Thromboembolic Events (TE) Among Patients with Inflammatory Bowel Disease (IBD)

Value in health, 2022-01, Vol.25 (1), p.S52-S52

2022

Volltextzugriff (PDF)

P1074 Impact of body mass index (BMI) on clinical outcomes and drug levels in patients with Crohn’s disease receiving maintenance treatment with subcutaneous infliximab: A post hoc analysis of the LIBERTY-CD study

Journal of Crohn's and colitis, 2024-01, Vol.18 (Supplement_1), p.i1930-i1931

2024

Volltextzugriff (PDF)

P874 Impact of immunogenicity on clinical outcomes in patients with Crohn’s disease receiving maintenance treatment with subcutaneous infliximab: A post hoc analysis of the LIBERTY-CD study

Journal of Crohn's and colitis, 2024-01, Vol.18 (Supplement_1), p.i1614-i1615

2024

Volltextzugriff (PDF)

PMU8 The Economic Burden of Thromboembolic Events Among Patients with Immune-Mediated Diseases

Value in health, 2021-06, Vol.24, p.S146-S146

2021

Volltextzugriff (PDF)

P577 A Phase 1b Study to Evaluate Safety, Tolerability, Pharmacokinetics and Clinical Efficacy of the Nucleotide-binding oligomerization domain, Leucine rich Repeat containing X1 (NLRX1) agonist NX-13 in Ulcerative Colitis

Journal of Crohn's and colitis, 2023-01, Vol.17 (Supplement_1), p.i705-i706

2023

Volltextzugriff (PDF)

P144 Modulation of Immunometabolism via NLRX1 or PLXDC2: Novel Bimodal Mechanisms for the Treatment of Inflammatory Bowel Diseases

Journal of Crohn's and colitis, 2024-01, Vol.18 (Supplement_1), p.i443-i445

2024

Volltextzugriff (PDF)

P524 Etrasimod shows low risk of adverse events following concomitant use with opioids or antidepressants in patients with ulcerative colitis

Journal of Crohn's and colitis, 2024-01, Vol.18 (Supplement_1), p.i1033-i1034

2024

Volltextzugriff (PDF)

DOP60 Simplified rules to identify bio-naïve patients with Crohn’s Disease with higher likelihood of clinical remission when initiating vedolizumab versus anti-TNFα therapies: Analysis of EVOLVE study data

Journal of Crohn's and colitis, 2021-05, Vol.15 (Supplement_1), p.S095-S096

2021

Volltextzugriff (PDF)

P552 Higher Serum Ustekinumab Levels Correlate With Higher Rates Of Steroid-Free Deep Remission And Endoscopic Healing In Patients With Inflammatory Bowel Diseases

Journal of Crohn's and colitis, 2022-01, Vol.16 (Supplement_1), p.i498-i499

2022

Volltextzugriff (PDF)

P476 Characterization of cardiac conduction abnormalities reported in the phase 3 ELEVATE programme

Journal of Crohn's and colitis, 2023-01, Vol.17 (Supplement_1), p.i604-i606

2023

Volltextzugriff (PDF)

P558 Etrasimod for the treatment of ulcerative colitis: analysis of infection rates from the phase 3 ELEVATE UC 52 and ELEVATE UC 12 clinical trials

Journal of Crohn's and colitis, 2023-01, Vol.17 (Supplement_1), p.i689-i690

2023

Volltextzugriff (PDF)

P407 Efficacy and safety of etrasimod in subjects with moderately to severely active isolated proctitis: a subgroup analysis of the phase 3 ELEVATE UC 52 and ELEVATE UC 12 trials

Journal of Crohn's and colitis, 2023-01, Vol.17 (Supplement_1), p.i536-i538

2023

Volltextzugriff (PDF)

P582 Efficacy of etrasimod at week 52 among subjects who reached clinical response at week 12: post hoc analysis of the phase 3 ELEVATE UC 52 trial

Journal of Crohn's and colitis, 2023-01, Vol.17 (Supplement_1), p.i709-i711

2023

Volltextzugriff (PDF)

P159 Patients with Inflammatory Bowel Disease Present with Lower Trabecular Bone Scores

Journal of Crohn's and colitis, 2021-05, Vol.15 (Supplement_1), p.S238-S239

2021

Volltextzugriff (PDF)

P632 Etrasimod induction therapy in moderately to severely active Crohn’s disease: results from a phase 2, randomised, double-blind substudy

Journal of Crohn's and colitis, 2023-01, Vol.17 (Supplement_1), p.i764-i765

2023

Volltextzugriff (PDF)

P682 Faecal calprotectin and C-reactive protein levels are associated with long-term clinical and endoscopic outcomes: Analysis of the OASIS open-label extension trial of etrasimod for ulcerative colitis

Journal of Crohn's and colitis, 2020-01, Vol.14 (Supplement_1), p.S555-S556

2020

Volltextzugriff (PDF)

DOP048 Vedolizumab levels during induction are associated with long-term clinical and endoscopic remission in patients with inflammatory bowel disease

Journal of Crohn's and colitis, 2018-01, Vol.12 (supplement_1), p.S064-S065

2018

Volltextzugriff (PDF)

1 – 25 von 406

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(390)
Mit Volltextzugriff
(312)

Publikationsform

Sprache

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(1)
... seit 90 Tagen
(3)

Menü

Weitere Dienste

Einstellungen

Higher infliximab trough levels are associated with perianal fistula healing in patients with Crohn's disease

The incidence and risk factors for developing depression after being diagnosed with inflammatory bowel disease: a cohort study

Vedolizumab in patients with concurrent primary sclerosing cholangitis and inflammatory bowel disease does not improve liver biochemistry but is safe and effective for the bowel disease

Letter: psychological remission ‐ a future endpoint in inflammatory bowel disease? Authors’ reply

Letter: is there a bi‐directional relationship between depression and IBD? Authors' reply

Higher Adalimumab Concentration Is Associated With Complete Fistula Healing in Patients With Perianal Fistulizing Crohn’s Disease

P739 Translating Pharmacokinetic and Efficacy Outcomes of NLRX1 Agonist NX-13: Contrasting a Pig Model and a Human Phase 1b Clinical Trial in Ulcerative Colitis

P114 Role of NLRX1 Agonist NX-13 in Reducing Visceral Hypersensitivity in Preclinical Gastrointestinal Inflammation

POSA96 The Economic Burden of Thromboembolic Events (TE) Among Patients with Inflammatory Bowel Disease (IBD)

P1074 Impact of body mass index (BMI) on clinical outcomes and drug levels in patients with Crohn’s disease receiving maintenance treatment with subcutaneous infliximab: A post hoc analysis of the LIBERTY-CD study

P874 Impact of immunogenicity on clinical outcomes in patients with Crohn’s disease receiving maintenance treatment with subcutaneous infliximab: A post hoc analysis of the LIBERTY-CD study

PMU8 The Economic Burden of Thromboembolic Events Among Patients with Immune-Mediated Diseases

P577 A Phase 1b Study to Evaluate Safety, Tolerability, Pharmacokinetics and Clinical Efficacy of the Nucleotide-binding oligomerization domain, Leucine rich Repeat containing X1 (NLRX1) agonist NX-13 in Ulcerative Colitis

P144 Modulation of Immunometabolism via NLRX1 or PLXDC2: Novel Bimodal Mechanisms for the Treatment of Inflammatory Bowel Diseases

P524 Etrasimod shows low risk of adverse events following concomitant use with opioids or antidepressants in patients with ulcerative colitis

DOP60 Simplified rules to identify bio-naïve patients with Crohn’s Disease with higher likelihood of clinical remission when initiating vedolizumab versus anti-TNFα therapies: Analysis of EVOLVE study data

P552 Higher Serum Ustekinumab Levels Correlate With Higher Rates Of Steroid-Free Deep Remission And Endoscopic Healing In Patients With Inflammatory Bowel Diseases

P476 Characterization of cardiac conduction abnormalities reported in the phase 3 ELEVATE programme

P558 Etrasimod for the treatment of ulcerative colitis: analysis of infection rates from the phase 3 ELEVATE UC 52 and ELEVATE UC 12 clinical trials

P407 Efficacy and safety of etrasimod in subjects with moderately to severely active isolated proctitis: a subgroup analysis of the phase 3 ELEVATE UC 52 and ELEVATE UC 12 trials

P582 Efficacy of etrasimod at week 52 among subjects who reached clinical response at week 12: post hoc analysis of the phase 3 ELEVATE UC 52 trial

P159 Patients with Inflammatory Bowel Disease Present with Lower Trabecular Bone Scores

P632 Etrasimod induction therapy in moderately to severely active Crohn’s disease: results from a phase 2, randomised, double-blind substudy

P682 Faecal calprotectin and C-reactive protein levels are associated with long-term clinical and endoscopic outcomes: Analysis of the OASIS open-label extension trial of etrasimod for ulcerative colitis

DOP048 Vedolizumab levels during induction are associated with long-term clinical and endoscopic remission in patients with inflammatory bowel disease

Suchergebnisse filtern